/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
We are a clinical-stage biopharmaceutical company focused on our Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+)…
$18.99
+$0.60 (+3.26%)
EOD Sep 18, 2026
ROIC dropped from -301.77% to -1064.25%, capital efficiency is deteriorating.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$22M
▼ -11.2% YoY
Op. Margin
—
ROIC
-655.33%
▼ -762.5pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$12M
▼ -36.4% YoY
Net Debt
-$9M
Net Cash Position
Cash & Equiv.
$9M
Continue Research
SourceComputed from the 10-Q filed 11 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 12 Aug 2026. How this is calculated.
Price from market data, last close as of 18 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.